Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Abstract: The invention relates to compositions and methods for treating proliferative pathologies, in particular cancers. The invention is based on the identification of particular properties of TReP-132 in the control of the cell cycle and in the control of cell proliferation. Said protein behaves as a tumor suppressor and is therefore a preferred target for developing efficient therapeutic strategies. The invention also relates to compositions, uses and methods for identifying compounds which can modulate the activity of said protein, and which can be used for treating different proliferative pathologies, in particular in humans.